Schedule 13D ownership disclosure
MBX Biosciences Inc
COMMON STOCK · CUSIP: 55287L101
Event date: 2025-09-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 4,002,887.00 · Class: 9.0%
- ORBIMED CAPITAL GP VII LLCReported CIK 0001760648
Shares: 3,255,000.00 · Class: 7.3%
- OrbiMed Genesis GP LLCReported CIK 0001808744
Shares: 747,887.00 · Class: 1.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000872
- Form type
- SCHEDULE 13D/A
- Filer
- MBX Biosciences, Inc.
- CIK
- CIK 1776111
- Filed
- Sep 30, 2025
- Reporting period
- Sep 26, 2025
- Description
- Schedule 13D beneficial ownership